Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 7/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630805 | 1.00 | CHRM4 (0.34) | CHRM4SMOFFAR2LRRK2LMNA | |
| SCHEMBL24423446 | 1.00 | CHRM4 (0.34) | CHRM4SMOFFAR2LRRK2LMNA | |
| SCHEMBL29584640 | 0.92 | CYP4F2 (0.36) | CHRM4SMOFFAR2LRRK2AKR1C3 | |
| SCHEMBL24423713 | 0.92 | CYP4F2 (0.36) | CHRM4SMOFFAR2LRRK2AKR1C3 | |
| SCHEMBL24424032 | 0.90 | CHRM4 (0.35) | CHRM4SMOFFAR2NPC1RAB9A | |
| SCHEMBL30630747 | 0.90 | CHRM4 (0.35) | CHRM4SMOFFAR2NPC1RAB9A | |
| SCHEMBL24423448 | 0.88 | MGLL (0.33) | CHRM4SMOFFAR2LRRK2NPC1 | |
| SCHEMBL29585305 | 0.88 | MGLL (0.33) | CHRM4SMOFFAR2LRRK2NPC1 | |
| SCHEMBL24423714 | 0.88 | MGLL (0.33) | CHRM4SMOFFAR2LRRK2NPC1 | |
| SCHEMBL29585591 | 0.87 | STS (0.39) | FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | CHRM4 1569/4885SMO 1469/4885FFAR2 16/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | CHRM4 289/4885SMO 1194/4885FFAR2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.